SCHEMBL6070955

SCHEMBL6070955

CSc1n[nH]c2c1CCc1c-2[nH]c2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 6/20 0.54
AURKB Q96GD4 2/20 0.54
MAPK10 P53779 6/20 0.51
RIPK1 Q13546 6/20 0.51
MEN1 O00255 6/20 0.51
KMT2A Q03164 6/20 0.51
MAPT P10636 5/20 0.51
RAB9A P51151 5/20 0.51
KDM4E B2RXH2 4/20 0.51
HSD17B10 Q99714 2/20 0.51
HPGD P15428 2/20 0.51
ALDH1A1 P00352 2/20 0.51
LMNA P02545 2/20 0.51
TSHR P16473 1/20 0.51
PTK2B Q14289 1/20 0.51
POLB P06746 3/20 0.47
ADRB2 P07550 1/20 0.47
HTR1A P08908 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071395 0.72 AURKA (0.50) AURKAAURKBMAPK10RIPK1MEN1
Hydrochloric Acid SCHEMBL6070901 0.71 AURKA (0.49) AURKAAURKBMAPK10RIPK1MEN1
SCHEMBL16786408 0.70 KDM4E (0.52) AURKAMAPK10RAB9AKDM4EHPGD
SCHEMBL29521187 0.70 KDM4E (0.52) AURKAMAPK10RAB9AKDM4EHPGD
SCHEMBL14297680 0.70 MEN1 (0.65) AURKAAURKBMAPK10RIPK1MEN1
SCHEMBL30489859 0.68 MAPK10 (1.00) AURKAMAPK10RIPK1MEN1KMT2A
SCHEMBL5583162 0.68 MAPK10 (1.00) AURKAMAPK10RIPK1MEN1KMT2A
SCHEMBL5918264 0.65 HSD17B10 (0.79) AURKAAURKBMAPK10RIPK1MEN1
SCHEMBL6070944 0.64 AURKA (0.49) AURKAAURKBMAPK10RIPK1MEN1
SCHEMBL9480941 0.64 MEN1 (1.00) AURKAAURKBMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US claimed
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed
EP-1599202-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-11-30 EP disclosed
WO-2004071507-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 AURKA 249/4885AURKB 369/4885MAPK10 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.